Careers

Diversity

With 17 offices, from New York to Los Angeles and Seattle to Orlando, we live and work in communities all over the U.S., collaborating across locations, disciplines and even borders. Our experienced, highly ranked lawyers serve businesses wherever they are and wherever they want to go.

Offices

About Us

Pages

Professionals

Thought leadership: blogs, podcasts, videos, publications, events and news

Insights

Services

Pro Bono

Am Law 100 firm with practices in Business, Digital Assets and Data Management, Intellectual Property, Labor & Employment, Litigation and Tax.

Home | BakerHostetler

What to Expect and How to Prepare: A Guide to Employing Foreign Workers in the Age of Trump

Teresa Goody Guillén Supports New SEC Nominee in Institutional Investor Article

Carolina Alonso Shares Her Journey to the Legal Profession with High School Students

​Bill Bergmann Elected Treasurer of Court of Federal Claims Bar Association; Continues Role on Advisory Council

J.D., Columbia Law School, 2017, 

B.S., San Diego State University, 2014, 

Orange County

BakerHostetler Represents GameSquare Holdings in FaZe Holdings Acquisition and Subsequent Joint Venture Formation

Business

Capital Markets and Securities

Capital Markets
<ul>
<li>Represented a multinational financial services firm and the underwriters in the following public underwritten offerings by a clinical-stage biotechnology company:
<ul>
<li>Underwritten offering of $172.5 million of common stock.</li>
<li>Initial public offering of $184 million of common stock on the Nasdaq.</li>
</ul>
</li>
<li>Represented the initial purchasers in the private offering of $575 million aggregate principal amount of convertible senior notes of a leading biotech company and the concurrent repurchase of 1 million of its American Depository Shares (ADSs).</li>
<li>Represented a multinational independent investment bank and financial services company and the underwriters in the underwritten offering of $135 million of common stock and pre-funded warrants of a late-stage biopharmaceutical company.</li>
<li>Represented a clinical-stage biopharmaceutical company in its proposed initial public offering of common stock (company was acquired before the transaction publicly flipped).</li>
<li>Represented a multinational investment bank and financial services company and the underwriters in the initial public offering of $660 million of common stock of a leading provider of accounts payable automation software and payment solutions on the Nasdaq, including the subsequent partial option exercise by the underwriters.</li>
<li>Represented a multinational investment bank and financial services company and the underwriters in the initial public offering of $92 million of common stock of a fashion brand for women on the Nasdaq.</li>
<li>Represented a multinational investment bank and the underwriters in the following public underwritten offerings by a biotechnology company:
<ul>
<li>Underwritten public offering of $144 million of common stock.</li>
<li>Initial public offering of $298.1 million of common stock on the Nasdaq.</li>
</ul>
</li>
<li>Represented a clinical stage biotherapeutics company in its initial public offering of $84.3 million of Class A common stock on the Nasdaq. The transaction involved an Up-C structure with the exchange of multiple classes of LLC units into shares of Class A and Class B common stock of the newly created holding corporation.</li>
<li>Represented an innovative biopharmaceutical company in its initial public offering of $222.9 million of common stock on the Nasdaq.</li>
<li>Represented a biotechnology company in its underwritten public offering of $115 million of common stock.</li>
<li>Represented a clinical-stage biotechnology company in its initial public offering of $276 million of common stock on the Nasdaq.</li>
</ul>
Public Companies
<ul>
<li>Served as counsel to a Nasdaq-listed clinical stage biopharmaceutical company in connection with its $22.4 million IPO.</li>
<li>Advised several Nasdaq-listed biopharmaceutical companies on securities reporting matters, including the drafting and review of annual reports, quarterly reports, current reports, proxy and information statements, Section 16 filings and S-3 and S-8 registration statements.</li>
<li>Represented a Nasdaq-listed biopharmaceutical company in connection with various corporate transactions, including an At-The-Market continuous offering program, disposition of certain drug product lines, and entry into credit facilities.</li>
<li>Represented a Nasdaq-traded agricultural company in a private investment in public equity (PIPE) offering of common stock.</li>
<li>Represented a Nasdaq-listed biotechnology company in several PIPE offerings of common stock, preferred stock and equity-linked debt securities.</li>
<li>Represented a Nasdaq-listed food production company in its entry into a $100 million equity line of credit.</li>
</ul>

Alexander M. Davis

Alexander M. Davis

Experience

Recognitions and Memberships

Insights and News

Credentials

Areas of Focus

Services

Featured Insights